A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation

CTCBIO

Status and phase: Unknown; Phase 2

Conditions: Premature Ejaculation

Treatments: Drug: Condencia-Placebo; Drug: Condencia; Drug: CDFR0812-Placebo; Drug: CDFR0812-15/25mg; Drug: CDFR0812-15/50mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT02571101

CTC-PED-CDFR0812_P2

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean Male Patients Diagnosed with Premature Ejaculation

Full description

Clomipramine is a dibenzazepine-derivative tricyclic antidepressant (TCA) and is a potent inhibitor of serotonin and norepinephrine reuptake. Clomipramine may be used in a variety of indications. Condencia Tab contains low dose of 15mg of clomipramine HCl as an active ingredient, which is newly approved to market for the treatment of premature ejaculation. This study is a prospective, randomized, double-blinded, active-control, 3-treatment arm, parallel, multi-center clinical trial. Approximately a total of 297 male patients diagnosed with premature ejaculation will be enrolled and randomized into 3 groups (99 subjects per a group).

The efficacy of oral administration of Clomipramine HCl will be investigated closely compared to the effects after oral administration of CDFR0812-15/25mg and CDFR0812-15/50mg.

The secondary object is to investigate general safety of oral administration of CDFR0812-15/25mg and CDFR0812-15/50mg.

Enrollment: 297 estimated patients

Sex: Male

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Korean male aged between 19 and 65
• Both patient and his partner given their informed and written consents
• Patient who has persisted for at least 6 months and is willing to retain the relationship during this study
• Patient diagnosed with premature ejaculation according to DSM-V
• Patient whose score in PEDT (Korean version) is 11 and more
• Patient who are willing to try 4 and more intercourse attempts for Run-in period and he has experienced 75%-100% of the IELT within one minute or less of vaginal penetration
• Patient whose personal distress in PEP is 'moderate' and over.
• Patient who is willing to participate in the study by the end and are cooperative (trying 4 and more intercourse attempts between each visit and able to postpone scheduled elective surgery)
• Patient who is willing to complete a patient diary and questionnaires

Exclusion criteria

• Patient who has a medical history including neurological disorders, infectious diseases, damage, surgery or medication history and that is judged to be related to premature ejaculation
• Patient who has participated into other trials within 90 days before this study
• Patient who is in a unstable medical condition or has alcohol/drug abuse in recent 6 months
• Patient whose female partner is less interested in sexual intercourse or has a sexual disorder
• Patient whose female partner is pregnant
• Patient whose female partner of childbearing age is not willing to use proper birth control
• Patient whose IIEF-EF score is 25 and less
• Medical history of convulsive diseases, mental diseases, E.C.T (Electroconvulsive shock Treatment), glaucoma
• Patient who has taken concomitantly prohibited medicines before the study and who is not willing to stop the medications for appropriate wash-out period

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

297 participants in 3 patient groups, including a placebo group

Test 1

Experimental group

Description:

Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.

Treatment:

Drug: Condencia-Placebo

Drug: CDFR0812-15/25mg

Test 2

Experimental group

Description:

Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.

Treatment:

Drug: Condencia-Placebo

Drug: CDFR0812-15/50mg

Comparator

Placebo Comparator group

Description:

Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.

Treatment:

Drug: Condencia

Drug: CDFR0812-Placebo